This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kohn, E. C. Articles by Liotta, L. A. Search for Related Content PubMed PubMed Citation Articles by Kohn, E. C. Articles by Liotta, L. A.

Clinical Investigation of a Cytostatic Calcium Influx Inhibitor in Patients with Refractory Cancers¹

Clinical Pharmacology Branch [E. C. K., E. R., G. S., M. C., C. J. L., W. D. F., P. A. D., J. J.] and Laboratory of Pathology [E. C. K., K. C., L. A. L.], National Cancer Institute, and Pharmacy Department, Warren G. Magnuson Clinical Center [B. G.], National Institutes of Health, Bethesda, Maryland 20892

Carboxyamido-triazole (CAI) is a synthetic inhibitor of non-excitable calcium channels that reversibly inhibits angiogenesis, tumor cell proliferation, and metastatic potential. Inhibition of calcium influx and calcium-dependent events is a potential common mechanism underlying these effects of CAI. The cytostatic and antiangiogenic properties of CAI led to its development for clinical investigation. In a Phase I clinical trial open to patients with refractory solid tumors, 49 patients received p.o. administered CAI daily or every other day. Two oral formulations, a PEG-400 CAI solution and a gelatin capsule containing CAI in PEG-400, were tested. All administered dosages of CAI yielded plasma concentrations at or above the range demonstrated to be effective in inhibiting signaling and cancer progression in vitro and in preclinical models (1 µg/ml, 2.3 µM). Toxicity of p.o. administered CAI most commonly consisted of dose-related grade 1–2 nausea, vomiting, and occasional anorexia. CAI administration at bedtime ameliorated gastrointestinal complaints in many patients; others required addition of simple antiemetic regimens, usually consisting of metoclopropamide or prochlorperazine. Gastrointestinal complaints were the cause for compliance-limiting toxicity at 175 mg/m²/day of the liquid formulation and 125 mg/m²/day of the gelatin capsule formulation. Reversible and rare sensory axonal neuropathy (grade 3, 1 patient) and neutropenia (grade 4, 1 patient) were dose-limiting toxicities observed at the 330 mg/m² every-other-day liquid CAI dose level. No evidence of cumulative end organ damage or central nervous system injury was observed. Disease stabilization and improvement in performance status was observed in 49% of evaluable patients who had disease progression before CAI. Disease stabilization and associated improvement in performance status was seen in patients with renal cell carcinoma (7 months), pancreaticobiliary carcinomas (3, 5, and 5 months), melanoma (7 months), ovarian cancer (7 months), and non-small cell lung cancer (3 months). The recommended Phase II doses from this trial are 150 mg/m²/day in the liquid formulation and 100 mg/m²/day in the gelatin capsule formulation.

¹ This work was supported in part by the G. Harold and Leila Y. Mathers Charitable Foundation.

² To whom requests for reprints should be addressed, at Signal Transduction and Prevention Unit, Laboratory of Pathology, Building 10, Room 2A33, 9000 Rockville Pike, Bethesda, MD 20892. Phone: (301) 496-9336; Fax: (301) 480-5142.

Received 8/17/95. Accepted 11/20/95.

This article has been cited by other articles:

				M. Koslowski, U. Sahin, K. Dhaene, C. Huber, and O. Tureci MS4A12 Is a Colon-Selective Store-Operated Calcium Channel Promoting Malignant Cell Processes Cancer Res., May 1, 2008; 68(9): 3458 - 3466. [Abstract] [Full Text] [PDF]

				A. F. Pla, C. Grange, S. Antoniotti, C. Tomatis, A. Merlino, B. Bussolati, and L. Munaron Arachidonic Acid-Induced Ca2+ Entry Is Involved in Early Steps of Tumor Angiogenesis Mol. Cancer Res., April 1, 2008; 6(4): 535 - 545. [Abstract] [Full Text] [PDF]

				W. M. Stadler, G. Rosner, E. Small, D. Hollis, B. Rini, S. D. Zaentz, J. Mahoney, and M. J. Ratain Successful Implementation of the Randomized Discontinuation Trial Design: An Application to the Study of the Putative Antiangiogenic Agent Carboxyaminoimidazole in Renal Cell Carcinoma--CALGB 69901 J. Clin. Oncol., June 1, 2005; 23(16): 3726 - 3732. [Abstract] [Full Text] [PDF]

				M. E. Winters, A. I. Mehta, E. F. Petricoin III, E. C. Kohn, and L. A. Liotta Supra-additive Growth Inhibition by a Celecoxib Analogue and Carboxyamido-triazole Is Primarily Mediated through Apoptosis Cancer Res., May 1, 2005; 65(9): 3853 - 3860. [Abstract] [Full Text] [PDF]

				A. J. Franklin, T. L. Jetton, C. L. Kuchemann, S. R. Russell, and E. C. Kohn CAI Is a Potent Inhibitor of Neovascularization and Imparts Neuroprotection in a Mouse Model of Ischemic Retinopathy Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3756 - 3766. [Abstract] [Full Text] [PDF]

				M. M. Hussain, H. Kotz, L. Minasian, A. Premkumar, G. Sarosy, E. Reed, S. Zhai, S. M. Steinberg, M. Raggio, V. K. Oliver, et al. Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer J. Clin. Oncol., December 1, 2003; 21(23): 4356 - 4363. [Abstract] [Full Text] [PDF]

				V. Chhokar and A. L. Tucker Angiogenesis: Basic Mechanisms and Clinical Applications Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 253 - 280. [Abstract] [PDF]

				A. Apati, J. Janossy, A. Brozik, P. I. Bauer, and M. Magocsi Calcium Induces Cell Survival and Proliferation through the Activation of the MAPK Pathway in a Human Hormone-dependent Leukemia Cell Line, TF-1 J. Biol. Chem., March 7, 2003; 278(11): 9235 - 9243. [Abstract] [Full Text] [PDF]

				G. L. Rosner, W. Stadler, and M. J. Ratain Randomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents J. Clin. Oncol., November 15, 2002; 20(22): 4478 - 4484. [Abstract] [Full Text] [PDF]

				J. Berlin, K. D. Tutsch, R. Z. Arzoomanian, D. Alberti, K. Binger, C. Feierabend, A. Dresen, R. Marnocha, J. Pluda, and G. Wilding Phase I and Pharmacokinetic Study of a Micronized Formulation of Carboxyamidotriazole, a Calcium Signal Transduction Inhibitor: Toxicity, Bioavailability and the Effect of Food Clin. Cancer Res., January 1, 2002; 8(1): 86 - 94. [Abstract] [Full Text] [PDF]

				E. A. Kruger and W. D. Figg Protein Binding Alters the Activity of Suramin, Carboxyamidotriazole, and UCN-01 in an ex Vivo Rat Aortic Ring Angiogenesis Assay Clin. Cancer Res., July 1, 2001; 7(7): 1867 - 1872. [Abstract] [Full Text] [PDF]

				E. C. Kohn, E. Reed, G. A. Sarosy, L. Minasian, K. S. Bauer, F. Bostick-Bruton, V. Kulpa, E. Fuse, A. Tompkins, M. Noone, et al. A Phase I Trial of Carboxyamido-triazole and Paclitaxel for Relapsed Solid Tumors: Potential Efficacy of the Combination and Demonstration of Pharmacokinetic Interaction Clin. Cancer Res., June 1, 2001; 7(6): 1600 - 1609. [Abstract] [Full Text] [PDF]

				S. Ge, S. A. Rempel, G. Divine, and T. Mikkelsen Carboxyamido-triazole Induces Apoptosis in Bovine Aortic Endothelial and Human Glioma Cells Clin. Cancer Res., April 1, 2000; 6(4): 1248 - 1254. [Abstract] [Full Text]

				K. S. Bauer, W. D. Figg, J. M. Hamilton, E. C. Jones, A. Premkumar, S. M. Steinberg, V. Dyer, W. M. Linehan, J. M. Pluda, and E. Reed A Pharmacokinetically Guided Phase II Study of Carboxyamido-triazole in Androgen-independent Prostate Cancer Clin. Cancer Res., September 1, 1999; 5(9): 2324 - 2329. [Abstract] [Full Text] [PDF]

				J. T. Weber, B. A. Rzigalinski, and E. F. Ellis Traumatic Injury of Cortical Neurons Causes Changes in Intracellular Calcium Stores and Capacitative Calcium Influx J. Biol. Chem., January 12, 2001; 276(3): 1800 - 1807. [Abstract] [Full Text] [PDF]